Phosphoramidate nucleoside derivatives as anticancer agents

A compound of formula (I) or a pharmaceutically acceptable salt thereof:

• wherein:
• R1 is aryl;
• R2 is selected from the group consisting of C1-C24-alkyl, C3-C24-alkenyl, C3-C24-alkynyl, C0-C4-alkylene-C3-C7-cycloalkyl and C0-C4-alkylene-aryl;
• R3 and R4 are each independently selected from the group consisting of H, C1-C6-alkyl and C1-C3-alkylene-R9;
• or R3 and R4 together with the atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl group;
• R5 and R7 are each independently selected from the group consisting of H and C1-C4-alkyl;
• R6 is independently selected from the group consisting of H and C(O)R10;
• R8 is independently selected from the group consisting of H, C(O)OR10 and C(O)R10;
• R9 is independently selected from the group consisting of aryl, imidazole, indole, SRa, ORa, CO2Ra, CO2NRaRa, NRaRb and NH(═NH)NH2;
• R10 is independently at each occurrence selected from the group consisting of C1-C24-alkyl, C3-C24-alkenyl, C3-C24-alkynyl, C0-C4-alkylene-C3-C7-cycloalkyl and C0-C4-alkylene-aryl;
• wherein any aryl group is selected from the group consisting of phenyl, naphthyl and tetrahydronaphthyl;
• and wherein any phenyl, alkyl, alkyne, alkene, alkylene, cycloalkyl, naphthyl or tetrahydronaphthyl group is optionally substituted with from 1 to 4 substituents selected from the group consisting of halo, nitro, cyano, NRaRa, NRaS(O)2Ra, NRaC(O)Ra, NRaCONRaRa, NRaCO2Ra, ORa, SRa, SORa, SO3Ra, SO2Ra, SO2NRaRa, CO2Ra C(O)Ra, CONRaRa, CRaRaNRaRa, C1-C4alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-haloalkyl;
• and
• wherein Ra is independently at each occurrence selected from the group consisting of H and C1-C4-alkyl;
• and Rb is independently at each occurrence selected from the group consisting of H, C1-C4-alkyl, C(O)—C1-C4-alkyl, and S(O)2—C1-C4-alkyl.